[{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Rioja Salud","sponsor":"Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Fundacion Rioja Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","highestDevelopmentStatusID":"1","companyTruncated":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Laboratorio Echevarne | Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Ritual Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Ritual Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Ritual Inc."},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Scripps Health \/ Undisclosed"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Vedistry Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Vedistry Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Vedistry Private Limited"},{"orgOrder":0,"company":"Northwell Health","sponsor":"National Library of Medicine | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ National Library of Medicine | Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ National Library of Medicine | Columbia University"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Kinderfarms","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinderfarms \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kinderfarms \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Larena SAS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"COLOMBIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Larena SAS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larena SAS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Larena SAS \/ Undisclosed"},{"orgOrder":0,"company":"Gustav Stalhammar","sponsor":"Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Gustav Stalhammar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gustav Stalhammar \/ Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Gustav Stalhammar \/ Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation"},{"orgOrder":0,"company":"Pharmamel","sponsor":"Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmamel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmamel \/ Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz","highestDevelopmentStatusID":"8","companyTruncated":"Pharmamel \/ Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz"},{"orgOrder":0,"company":"Lone Baandrup","sponsor":"Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Lone Baandrup","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lone Baandrup \/ Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark","highestDevelopmentStatusID":"9","companyTruncated":"Lone Baandrup \/ Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark"}]
Find Clinical Drug Pipeline Developments & Deals for Melatonin
Details :
Slenyto is a child appropriate Extended-release oral minitablet (only 3mm diameter), containing melatonin, a naturally occurring hormone that regulates the sleep-wake cycle.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is a cannabinoid-based partial CB1 receptor agonist with anti-neuroinflammatory and neuroprotective properties. It is being evaluated for the treatment of dementia due to Alzheimer's disease.
Details :
Slenyto is a prolonged-release formulation of melatonin, which is indicated for the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).
Details :
Slenyto (melatonin) is an approved melatonin receptor agonist, which is currently being evaluated for the treatment of insomnia in children with neurogenetic disorders.
Sponsor :
University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Details :
Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Low Back Pain.
Sponsor :
University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Details :
IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pressure Ulcer.
Reset All
